… Acenocoumarol and warfarin have different half-lives and it is not … effectiveness and safety
of acenocoumarol, warfarin, dabigatran, rivaroxaban, apixaban and edoxaban in patients …

… this real-world study, we found that the effectiveness and safety profiles of NOAC and
acenocoumarol … However, in high-risk subgroups, our findings on the efficacy and safety of certain …

… In conclusion, NOACs were associated with a superior long-term effectiveness and non-inferior
to superior safety compared to VKAs in an unselected real-world population with AF. …

… 32,476 participants) [49] used acenocoumarol, and in nine of the … dabigatran has a favorable
impact on effectiveness and safety outcomes compared with VKA in non-Asian real-world …

… , acenocoumarol and general VKAs were combined into a single VKA node. Given that there
were only a limited number of studies that included phenprocoumon or acenocoumarol and …

… in patients with complex comorbid conditions such as chronic kidney disease [8,9] and active
cancer [10], clinical trial and real-world … and warfarin or acenocoumarol. Although causal …

… In conclusion, the effectiveness and safety results, consistency with final Phase II of GLORIA-AF,
and other real-world registries provide evidence of the benefit and safety of dabigatran …

… real-world use coincides greatly with them. Vitamin K antagonists (warfarin and acenocoumarol)
… This study aimed to summarize real-world data on comparative bleeding risks between …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with increasing
prevalence over the past decades. 1, 2 Patients with AF increased risk for hospitalization, …

… or acenocoumarol (with enoxaparin bridging) and was associated with a similar risk for
bleeding (7, 8). Randomized clinical trials comparing apixaban with rivaroxaban in patients with …